Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica
NCT00541476
Last updated date
ABOUT THIS STUDY
The purpose of this study is to obtain more data about efficacy and safety of the study drug
Lyrica.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Clinical diagnosis of peripheral or central neuropathic pain
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- None. Patients recruited by physician decision. Patient's personal data are not
collected.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
NeuralgiaA Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain
NCT00631943
- Bangalore, Karnataka / India
- Bangalore, Karnataka
- Mumbai, Maharashtra
- Maharashtra, Mumbai
- Chennai, Tamil Nadu
- Chennai, Tamil, Nadu
ALL GENDERS
18 Years+
years
MULTIPLE SITES
NeuralgiaSafety And Efficacy Of Lyrica (Regulatory Post Marketing Commitment Plan)
NCT01256593
ALL GENDERS
0+
years
MULTIPLE SITES
NeuralgiaNon-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica
NCT00541476
ALL GENDERS
18 Years+
years
MULTIPLE SITES
NeuralgiaTo Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
NCT00150436
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Treated With Lyrica | |||
| Official Title | Non-Interventional Study In Patients With Peripheral Or Central Neuropathic Pain Undergoing Symptomatic Treatment With Lyrica | |||
| Brief Summary | The purpose of this study is to obtain more data about efficacy and safety of the study drug Lyrica. | |||
| Detailed Description | Not Provided | |||
| Study Type | Observational | |||
| Study Design | Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Not Provided | |||
| Study Population | Not Provided | |||
| Condition | Neuralgia | |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 746 | |||
| Original Enrollment | 750 | |||
| Actual Study Completion Date | December 2007 | |||
| Actual Primary Completion Date | December 2007 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00541476 | |||
| Other Study ID Numbers | A0081178 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
| Study Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | November 2008 | |||